A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).
Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
DRUG: AL2846 capsules
Adverse event rate, The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs), :Baseline up to 96 weeks|objective response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., Baseline up to 96weeks
Phase II clinical recommended dose （RP2D）, recommended dose of Phase II clinical trial, Baseline up to 96 weeks|Progression-free survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 96 weeks|Duration of Response (DOR), The time when the participants first achieved complete or partial remission to disease progression., up to 96 weeks|PFS rate of one year, Rate of patients with PFS reaching one year among all patients, up to 96 weeks|Overall Survival（OS）, From date of first administration of test drug until the date of death from any cause, assessed up to100 months|Pain Scale (self-report form), Self-report of pain in target tumor and other parts of body, up to 96 weeks|Quality of life related scale（European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0, EORTC QLQ-C30(V3)）, Questionnaires about the quality of life (including mental state, appetite state, sleep, etc.), up to 96 weeks|The patient's overall impression of the severity of symptoms (self-report), Self-report on the severity of tumor pain, overall pain status, and tumor-related problems other than pain (vision, hearing, mobility, hearing, appearance, etc.), up to 96 weeks
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).